Broadly neutralizing HIV antibodies (bnAbs) are typically highly somatically mutated, raising
doubts as to whether they can be elicited by vaccination. We used 454 sequencing and …

HIV broadly neutralizing antibodies (bnAbs) can suppress viremia and protect against HIV
infection. However, their elicitation is made difficult by low frequencies of appropriate …

Broadly neutralizing antibodies (bnAbs) targeting the trimer apex of HIV envelope are favored
candidates for vaccine design and immunotherapy because of their great neutralization …

A vaccine that elicits broadly neutralizing antibodies (bNAbs) against HIV-1 is likely to be
protective, but this has not been achieved. To explore immunization regimens that might elicit …

Induction of broadly neutralizing antibodies (bnAbs) is a primary goal of HIV vaccine
development. VRC01-class bnAbs are important vaccine leads because their precursor B cells …

The HIV envelope glycoprotein (Env) is densely covered with self-glycans that should help
shield it from recognition by the human immune system. Here, we examine how a particularly …

Broadly neutralizing monoclonal antibodies (bnmAbs) that target the high-mannose patch
centered around the glycan at position 332 on HIV Env are promising vaccine leads and …

No immunogen to date has reliably elicited broadly neutralizing antibodies to HIV in humans
or animal models. Advances in the design of immunogens that antigenically mimic the HIV …

The dense patch of high-mannose-type glycans surrounding the N332 glycan on the HIV
envelope glycoprotein (Env) is targeted by multiple broadly neutralizing antibodies (bnAbs). …

The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of
neutralizing various HIV-1 viral strains is challenging, but understanding how a subset of HIV-…